Abstract
Cholangiocarcinoma (CCA) is a rare malignancy with a very poor prognosis. Considering that most cases of CCAare diagnosed at a locally advanced stage and the standard of care for advanced CCA remains suboptimal, new prognostic and predictive biomarkers must be developed to improve the management and survival of patients diagnosed with CCAregardless of disease stage. According to recent studies, 20% of biliary tract cancers exhibit theBRCAness phenotype, meaning that these tumors do not havegermline mutations in BRCA but share phenotypic traits with tumors that possess hereditary BRCA mutations. Therefore, screening for these mutations in CCA patients is beneficial to predicttumorsensitivity and response to DNA-damaging chemotherapy such as platinum agents.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
